Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

This study has been completed.
Sponsor:
Collaborators:
Novartis Pharmaceuticals
Sanofi
Walther Cancer Institute
Information provided by (Responsible Party):
Daniela Matei, MD, Hoosier Cancer Research Network
ClinicalTrials.gov Identifier:
NCT00216112
First received: September 12, 2005
Last updated: February 17, 2016
Last verified: February 2016